Medidata Selected by ICON to Evolve Image Management and Accelerate Research Goals for Sponsors and Sites During Clinical Tri...
November 15 2017 - 8:30AM
Business Wire
Medidata Medical Imaging® Provides End-to-End
Control of Rapidly Growing Data Source
Medidata (NASDAQ: MDSO), the leading global provider of
cloud-based solutions and data analytics for clinical research, and
ICON (NASDAQ: ICLR), a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and
medical device industries, today announced a new collaboration to
enhance the management of medical imaging during drug development
research. ICON will expand its use of the Medidata Clinical Cloud®
to include image management services for end-to-end digital control
of the healthcare industry’s fastest growing data source.
ICON, a Medidata CRO partner since 2005, will now leverage
Medidata Medical Imaging® to manage imaging studies through a
single, unified cloud platform. With Medidata imaging technology,
ICON customers, including sponsors and sites, will have the added
benefit of configurable and near real-time image access; enhancing
speed and facilitating analysis during clinical trials.
“Imaging biomarkers have become a key element in clinical trial
design and are a valuable resource in enabling early decision
making and pipeline management,” commented Paul McCracken, ICON’s
VP Imaging. “By adding Medidata imaging to our market-leading
expertise and suite of technology assets, we are streamlining the
management of images during clinical trials, which will help to
improve quality and reduce the cycle times associated with medical
image management.”
Medidata Medical Imaging works seamlessly with the Medidata
Clinical Cloud or as a stand-alone solution, enabling efficient
workflow management and flexibility. The Medidata solution
automates the distribution and review process after the image
upload; reducing the time associated with image management, while
increasing data quality and confidence.
“We are proud to be a long time partner of ICON, and our new
collaboration reinforces ICON’s dedication to facilitating the
discovery of new patient solutions,” said Wade Wirta, managing
director, Medidata. “Imaging technology is opening new doors during
the drug development process, from the monitoring of outcomes to
therapy responses. With the Medidata cloud platform, researchers
can efficiently leverage imaging to accelerate clinical trial
breakthroughs.”
About Medidata:Medidata is reinventing global drug and
medical device development by creating the industry's leading
cloud-based solutions for clinical research. Through our advanced
applications and intelligent data analytics, Medidata helps advance
the scientific goals of life sciences customers worldwide,
including over 950 global pharmaceutical companies, biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
About ICON plcICON plc is a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis
of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in
Dublin, Ireland, ICON currently, operates from 97 locations in 38
countries and has approximately 13,100 employees. Further
information is available at www.iconplc.com/imaging.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115005717/en/
Medidata SolutionsInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Sep 2023 to Sep 2024